20 million Europeans with ADHD await solution
- Expert VHIR show that methylphenidate, as used in children with this disorder, is effective in adults
Barcelona, \u200b\u200bFebruary 2011 .- A review study led by the Vall d'Hebron, Institut de Recerca (VHIR) has confirmed the efficacy of methylphenidate for adults Deficit Disorder Attention Hyperactivity Disorder (ADHD). So far, the European Union authorizes treatment with methylphenidate (a stimulant) for children with Attention Deficit Disorder with Hyperactivity (ADHD), but there are 20 million adults with the same disease and treatment are orphans, but is expected This study serves to provide sufficient evidence of the benefits of its use. 
Reason of this paradox is that the studies done previously concluded with mixed results regarding the efficacy of methylphenidate. In fact, there had been many studies whose results were very mixed, from the ineffective to a great improvement, but the study by this group of experts from the Hospital Universitari Vall d'Hebron, not only demonstrates the usefulness of this drug for the treatment in adults with ADHD, but has also identified the factors responsible for this discrepancy of results. And even more refined: the study states the best way of administration of this medication in adults.
Reason of this paradox is that the studies done previously concluded with mixed results regarding the efficacy of methylphenidate. In fact, there had been many studies whose results were very mixed, from the ineffective to a great improvement, but the study by this group of experts from the Hospital Universitari Vall d'Hebron, not only demonstrates the usefulness of this drug for the treatment in adults with ADHD, but has also identified the factors responsible for this discrepancy of results. And even more refined: the study states the best way of administration of this medication in adults. Methylphenidate is effective in adults with ADHD
decades methylphenidate used safely in children, although this treatment has been demonized stimulating and often have referred to him as if they were amphetamines. It has been shown that its use is safe and effective and that its inhibitory effect on the reuptake of norepinephrine and dopamine in the brain achieves the desired effect on the control of symptoms in these children. Whether the presence of opponents of the use of this drug, either by ignorance of this disorder can also affect adults, studies in these cases was insufficient. Because of this controversy, and with the help of a meta-analysis of studies done now, experts have VHIR conducted this analysis to discover the effectiveness of methylphenidate to symptoms of ADHD in adults. This review, recently published in CNS Drugs, sought to examine separately the influence of various factors on the efficacy of methylphenidate in adults with ADHD. 
makers of this analysis, after reviewing the 17 previous studies have identified factors that may have been the cause of the heterogeneity of the results of these studies: the administration of the drug in an uncontrolled way, without defining the dose as very suitable (usually insufficient), the existence of disturbances added to ADHD and to reduce effectiveness of treatment (drug addictions) and release form of the drug (pharmacokinetics).
Dr. Ramos-Quiroga and his team proceeded to evaluate each of these factors and found, as he explains, "that the effectiveness of treatment increases with the number of doses supplied, that the effectiveness of methylphenidate is less when the release of the drug in the blood is continuous, prolonged and constant, while the treatment is ideal for when the drug is released in bursts, and decreases the effectiveness of treatment in patients consuming toxic substances. Regarding the other variables were not significant effects on perceived efficiency. " In this way it has been concluded that methylphenidate is effective for adults with ADHD when administered properly. 
makers of this analysis, after reviewing the 17 previous studies have identified factors that may have been the cause of the heterogeneity of the results of these studies: the administration of the drug in an uncontrolled way, without defining the dose as very suitable (usually insufficient), the existence of disturbances added to ADHD and to reduce effectiveness of treatment (drug addictions) and release form of the drug (pharmacokinetics). Although further studies are necessary for the EU to approve the use of methylphenidate in adults with ADHD, the analytical work conducted by experts from Vall d'Hebron Hospital have been submitted to the Jadad scale has corroborated the quality of the study and turn determine the impossibility of drawing conclusions from previous studies. ADHD often disabling illness that affects both adults and children
ADHD experts Hospital Universitari Vall d'Hebron and his research group in VHIR have already participated in several discoveries in this field. One of the most significant dates back to 2008, when they discovered that there are some common genetic basis for ADHD ADHD in children and adults, thus reinforced the hypothesis of genetic disorder and, therefore, that it is the same condition in the two population groups rather than two separate disorders. In addition, it began to suggest genetic differences between populations of patients whose symptoms referred to adulthood and the population in which the condition persists beyond childhood. Attention Deficit Hyperactivity Disorder is a chronic disorder early childhood, which is estimated to affect 4.4% of adults. In the latter group of people, ADHD manifests itself in difficulties at work, psychological disabilities and a high risk of mood disorders, anxiety and substance abuse. But the treatment that this group of people has been received so far, accompanied by controversy: methylphenidate was usually recommended as one of the first pharmacological treatment options, without having solid research to substantiate its effectiveness.
SOURCE: http://www.noticiasmedicas.es/medicina/noticias/7125/1/Se-demuestran-los-beneficios-de-un-farmaco-no-autorizado-para-el-tratamiento-del-TDAH -en-adultos-/Page1.html
0 comments:
Post a Comment